Astrazeneca (AZN) Interest Expenses (2016 - 2026)

Astrazeneca has reported Interest Expenses over the past 16 years, most recently at -$393.0 million for Q1 2026.

For Q1 2026, Interest Expenses fell 12.61% year-over-year to -$393.0 million; the TTM value through Mar 2026 reached -$1.8 billion, down 4.29%, while the annual FY2025 figure was $1.7 billion, 2.76% down from the prior year.
Interest Expenses for Q1 2026 was -$393.0 million at Astrazeneca, up from -$484.0 million in the prior quarter.
Over five years, Interest Expenses peaked at -$311.0 million in Q2 2022 and troughed at -$484.0 million in Q4 2025.
A 5-year average of -$401.2 million and a median of -$413.0 million in 2024 define the central range for Interest Expenses.
Biggest five-year swings in Interest Expenses: crashed 1144.44% in 2022 and later increased 15.5% in 2025.
Year by year, Interest Expenses stood at -$360.0 million in 2022, then dropped by 23.61% to -$445.0 million in 2023, then grew by 3.6% to -$429.0 million in 2024, then fell by 12.82% to -$484.0 million in 2025, then increased by 18.8% to -$393.0 million in 2026.
Business Quant data shows Interest Expenses for AZN at -$393.0 million in Q1 2026, -$484.0 million in Q4 2025, and -$434.0 million in Q3 2025.

Peer Comparison